Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Interim results from this Chinese study (n=267) demonstrate that pyrotinib plus capecitabine significantly improved progression-free survival vs lapatinib plus capecitabine (12.5 vs 6.8 months; HR 0.39; 95% CI 0.27–0·56]; p<0.0001) with similar serious adverse events (10% vs 8%).

Source:

The Lancet Oncology